Johnson & Johnson executive Tom Cavanaugh provided a data-rich update at the Goldman Sachs Global Healthcare Conference on June 9. He signaled that the company’s new drug pipeline is progressing faster than current analyst projections.
Cavanaugh disclosed that ICOTYDE, a new oral treatment for moderate-to-severe plaque psoriasis, has secured approximately 4,500 prescribers. This figure represents a substantial increase in uptake since the first quarter.
The drug appears to expand the market by attracting patients who are not currently on advanced systemic treatments. This strategy allows J&J to grow without relying solely on taking market share from competitors.
Strong initial metrics for ICOTYDE are critical as J&J navigates the loss of exclusivity for its blockbuster drug, STELARA. The company relies on this new product pipeline to sustain its future growth trajectory.